Thousands report GLP‑1 side effects online
A new study using public social‑media data finds thousands of people are sharing side‑effects from GLP‑1 weight‑loss drugs that may not be captured in clinical visits. (bnnbloomberg.ca) The reporting highlights a range of patient‑reported experiences being posted publicly and raises questions about how clinicians track and evaluate those symptoms. (bnnbloomberg.ca)
A University of Pennsylvania team used artificial intelligence to scan Reddit posts and found thousands of people describing glucagon-like peptide-1 drug side effects that may not show up in clinic visits. (nature.com) The study, published April 10 in *Nature Health*, analyzed 410,198 Reddit posts from May 2019 through June 2025 that mentioned semaglutide or tirzepatide. Of 67,008 users who said they were taking one of the drugs, 43.5% reported at least one side effect. (nature.com) The most common complaints were stomach-related: nausea in 36.9% of users reporting side effects, fatigue in 16.7%, vomiting in 16.3%, constipation in 15.3%, and diarrhea in 12.6%. The researchers also flagged menstrual irregularities and temperature-related symptoms such as chills and hot flashes as signals not well captured in current labels or trials. (nature.com) These drugs slow digestion and affect appetite and blood sugar, which is why nausea, vomiting, constipation, and diarrhea already appear on United States drug labels for Wegovy and Zepbound. Federal prescribing information also lists fatigue among common adverse reactions. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The new paper focuses on what patients say outside formal reporting systems. Senior author Sharath Chandra Guntuku said the method picked up known effects such as nausea, which suggested the system was finding a real signal, and then surfaced less-studied complaints that “came from patients themselves, unprompted.” (seas.upenn.edu) The authors said the Reddit findings do not prove the drugs caused the symptoms. First author Neil Sehgal said nearly 4% of users in the sample reported menstrual irregularities and called that “a signal worth investigating,” not a causal conclusion. (seas.upenn.edu) Use of these medicines has grown far beyond diabetes care. A KFF poll published May 10, 2024 found 12% of United States adults said they had ever taken a glucagon-like peptide-1 drug, including 6% who said they were taking one at the time. (kff.org) That scale helps explain why researchers are looking for side effects in places other than clinical trials, which are smaller, shorter, and built around predefined questions. The Penn team said large-scale social-media analysis can complement traditional drug-safety monitoring by spotting concerns patients discuss in real time. (nature.com) (seas.upenn.edu) The study does not change prescribing guidance on its own, but it adds a new stream of patient-reported evidence as use of semaglutide and tirzepatide keeps expanding. For doctors and regulators, the next step is the slower one: testing whether the symptoms people post about online hold up in clinical data. (nature.com)
